Innovations in wound medicine

Wound Medicine

Volumn 4, Issue , 2014, Pages 9-12

  Günter, Christina Irene ^a   Machens, Hans Günther ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chronic wounds; Wound healing; Wound treatment

Indexed keywords

EPIDERMAL GROWTH FACTOR; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; KERATINOCYTE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BIOMEDICINE; BURN; CELL ACTIVATION; CHRONIC WOUND; DECUBITUS; DEEP DERMAL WOUND; DEEP WOUND; DIABETIC ULCER; EPITHELIZATION; GENE THERAPY; HUMAN; NEUROPATHIC ULCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGENERATIVE ABILITY; REGENERATIVE MEDICINE; SKIN INJURY; STEM CELL; STEM CELL TRANSPLANTATION; SUPERFICIAL DERMAL WOUND; SUPERFICIAL WOUND; THROMBOCYTE RICH PLASMA; TISSUE ENGINEERING; TISSUE INJURY; ULCER; WOUND CARE; WOUND HEALING; WOUND MEDICINE;

EID: 84896541203     PISSN: 22139095     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.wndm.2013.11.001     Document Type: Article

References (38)

1. Horch R.E., Nord D., Augustin M., Germann G., Leffler M., Dragu A. Ökonomische Aspekte in der chirurgischen Wundbehandlung. Chirurg 2008, 79:518-525.
2. Galeano M., Altavilla D., Cucinotta D., Russo G.T., Calò M., Bitto A., et al. Recombinant human EPO stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetes 2004, 53:2509-2517.
3. Buemi M., Galeano M., Sturiale A., Ientile R., Crisafulli C., Parisi A., et al. Recombinant human EPO stimulates angiogenesis and healing of ischemic skin wounds. Shock 2004, 22:169-173.
4. Galeano M., Altavilla D., Bitto A., Minutoli L., Calò M., Lo Cascio P., et al. Recombinant human EPO improves angiogenesis and wound healing in experimental burn wounds. Crit Care Med 2006, 34:1139-1146.
5. Hamed S., Ullmann Y., Masoud M., Hellou E., Khamaysi Z., Teot L. Topical EPO, promotes wound repair in diabetic rats. J Invest Dermatol 2010, 130:287.
6. Sorg H., Krueger C., Schulz T., Menger M.D., Schmitz F., Vollmar B. Effects of EPO in skin wound healing are dose related. FASEB J 2009, 23:1-10.
7. Bader A., Machens H.G. Recombinant human EPO plays a pivotal role as a topical stem cell activator to reverse effects of damage to the skin in aging and trauma. Rejun Res 2010, 13:499.
8. Bader A., Ebert S., Giri S., Kremer M., Liu S., Nerlich A., et al. Skin regeneration with conical and hair follicle structure of deep second-degree scalding injuries via combined expression of the EPO receptor and beta common receptor by local subcutaneous injection of nanosized rhEPO. Int J Nanomed 2012, 7:1227-1237.
9. Ferri C., Giuggioli D., Sebastiani M., Colaci M. Treatment of severe scleroderma skin ulcers with recombinant human EPO. Clin Exp Dermatol 2007, 32:287-290.
10. Keast D.H., Fraser C. Treatment of chronic skin ulcers in individuals with anemia of chronic disease using rhEPO: a review of four cases. Ostomy Wound Manage 2004, 50:64-70.
11. Driver V.R., Hanft J., Fylling C.P., Beriou J.M. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage 2006, 52:68-70. Autologel Diabetic Foot Ulcer Study Group, 72,74.
12. Pietrzak W.S., Eppley B.L. Platelet rich plasma: biology and new technology. J Craniofac Surg 2005, 16:1043-1054.
13. Eppley B.L., Pietrzak W.S., Blanton M. Platelet rich plasma: a review of biology and applications in plastic surgery. Plast Reconstr Surg 2006, 118:147e-159e.
14. Lacci K.M., Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med 2010, 83:1-9.
15. Metha S., Watson T.J. Platelet-rich concentrate: basis science and current clinical applications. J Orthop Trauma 2008, 22:432-438.
16. Marx R.E. Platelet-rich plasma (PRP): what is PRP and what is not PRP. Implant Dent 2001, 10:225-228.
17. Eppley B.L., Woodell J.E., Higgins J. Platelet quantifications and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 2004, 114:1502-1508.
18. Millington J.T., Norris T.W. Effective treatment strategies for diabetic foot wounds. J Fam Pract 2000, 49:40-48.
19. Knighton D.R., Ciresi K.F., Fiegel V.D., Austin L.L., Butler E.L. Classification and treatment of chronic nonhealing wounds Successful treatment with autologous platelet-derives wound healing factors. Ann Surg 1986, 204:322-330.
20. Mishra A., Woodall J., Vieira A. Treatment of tendon and muscle using PRP. Clin Sports Med 2009, 28:113-125.
21. Falanga V. Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair Regen 2000, 8:347-352.
22. Robson M.C. Growth factors as wound healing agents. Curr Opin Biotechnol 1991, 2:863-867.
23. Robson M.C., Phillips L.G., Lawrence W.T., Bishop J.B., Youngerman J.S., Hayward P.G., et al. The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann Surg 1992, 216:401-406. [discussion 406-8].
24. Pierce G.F., Tarpley J.E., Tseng J., Bready J., Chang D., Kenney W.C., et al. Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence in PDGF in chronic nonhealing wounds. J Clin Invest 1995, 96:1336-1350.
25. Pierce G.F., Tarpley J.E., Allman R.M., Goode P.S., Serdar C.M., Morris B., et al. Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB. Am J Pathol 1994, 145:1399-1410.
26. Smiell J.M., Wieman T.J., Steed D.L., Perry B.H., Sampson A.R., Schwab B.H. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999, 7:335-346.
27. Steed D.L., Donohoe D., Webster M.W., Lindsley L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg 1996, 183:61-64.
28. Vogt P.M., Thompson S., Andree C., Liu P., Breuing K., Hatzis D., et al. Genetically modified keratinocytes transplanted to wounds reconstitute the epidermis. Proc Natl Acad Sci U S A 1994, 91:9307-9311.
29. Eming S.A., Medalie D.A., Tompkins R.G., Yarmush M.L., Morgan J.R. Genetically modified human keratinocytes overexpressing PDGF-A enhance the performance of a composite skin graft. Hum Gene Ther 1998, 9:529-539.
30. Nikol S. Therapeutische Angiogenese mittels Gen- und Stammzellentherapie bei der peripheren arteriellen Verschlusskrankheit. Dtsch med Wochenschr 2011, 136:672-674.
31. Lorenz K., Sicker M., Schmelzer E., Rupf T., Salvetter J., Schulz-Siegmund M., et al. Multilineage differentiation potential of human dermal skin-derived fibroblasts. Exp Dermatol 2008, 17:925-932.
32. Toma J.G., Akhavan M., Fernandes K.J., Barnabé-Heider F., Sadikot A., Kaplan D.R., et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol 2001, 3:778-784.
33. Egaña J.T., Danner S., Kremer M., Rapoport D.H., Lohmeyer J.A., Dye J.F., et al. The use of glandular-derived stem cells to improve vascularization in scaffold-mediated dermal regeneration. Biomaterials 2009, 1-9.
34. Bader A., Lorenz K., Richter A., Scheffler K., Kern L., Ebert S., et al. Interactive Role of Trauma Cytokines and EPO and their therapeutic potential for acute and chronic wounds. Rejun Res 2011, 14:57-66.
35. Amann B., Lüdemann C., Ratei R., Schmidt-Lucke J.A. Extremitätenerhalt durch autologe Knochenmarksstammzelltransplantation zur Induktion der Arteriogenese bei kritischer, nicht-revaskularisierbarer Extremitätenischämie. Chirurgie 2009, 134:298-304.
36. Tateishi-Yuyama E., Matsubara H., Murohara T., Ikeda U., Shintani S., Masaki H., et al. Therapeutic angiogenesis for patients with limb ischaemia b autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002, 360:427-435.
37. Hollander D.A. Reconstruction of extensive soft tissue loss by transplantation of dermal and epidermal equivalents. Zentralbl Chir 2004, 129:29-36.
38. Kirsner R.S., Falanga V., Eaglstein W.H. The development of bioengineered skin. Trends Biotechnol 1998, 16:246-249.